Chronische lymphatische Leukämie und Haarzellenleukämie

Bennett, J. M., D. Catovsky, M.-T. Daniel, G. Flandrin, D. A. G. Galton, H. R. Gralnick, C. Sultan, The French-American-British (FAB) Cooperative Group: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J. clin. Path. 42 (1989), 567–584.

Binet, J. L., A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen, G. Vaugier, G. Potron, P. Colona, F. Oberling, M. Thomas, G. Tchernia, C. Jacquillat, P. Boivin, C. Lesty, M. T. Duault, M. Monconduit, S. Belabbes, F. Gremy A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer (Philad.) 48 (1981), 198–206.

Brittinger, G., H. Bartels, H. Common, E. Dühmke, H. H. Fülle, U. Gunzer, T. Gyenes, R. Heinz, E. König, P. Meusers, M. Paukstat, H. Pralle, H. Theml, W. Köpcke, C. Thieme, T. Zwingers, K. Musshoff, A. Stacher, H. Brücher, F. Herrmann, W. D. Ludwig, W. Pribilla, A. Burger-Schüler, G. W. Löhr, H. Gremmel, J. Oertel, H. Gerhartz, K. M. Koeppen, I. Boll, D. Huhn, T. Binder, A. Schoengen, L. Nowicki, H. W. Pees, P. G. Scheurlen, H. Leopold, M. Wannenmacher, M. Schmidt, H. Löffler, G. Michlmayr, E. Thiel, R. Zettel, U. Rühl, H. J. Wilke, E. W. Schwarze, H. Stein, A. C. Feller, K. Lennert (Kiel Lymphoma Study Group): Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas: Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol. Oncol. 2 (1984), 269–306.

Cheson, B. D., J. M. Bennett, M. Grever, N. Kay, M. J. Keating, S. O’Brien, K. R. Rai: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87 (1996), 4990–4997.

Dighiero, G., P. Travade, S. Chevret, P. Fenaux, C. Chastang, J. L. Binet and The French Cooperative Group on CLL: B-cell chronic lymphocytic leukemia: Present status and future directions. Blood 78 (1991), 1901–1914.

Döhner, H., K. Fischer, M. Bentz, K. Hansen, A. Benner, G. Cabot, D. Diehl, R. Schlenk, J. Coy, S. Stilgebauer, M. Volkmann, P. R. Galle, A. Poustka, W. Hunstein, P. Lichter: p53 gene delection predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995), 1580–1589.

Engelhard, M., G. Brittinger, R. Heinz, H. Theml, H. Bartels, T. Binder, H. H. Fülle, H. Gerhartz, U. Gunzer, F. Ludwig, W. D. Ludwig, L. Nowicki, J. Oertel, H. W. Pees, H. Pralle, U. Rühl, Ch v. Schilling, W. Spann, A. Stacher, U. Szeimies, H. J. Wetzel, T. Zwingers, A. C. Feller, H. Stein, K. Lennert (Kiel Lymphoma Study Group, Germany and Austria): Chronic lymphocytic leukemia (B-CLL) and immunocytoma (LP-IC): Clinical and prognostic relevance of this distinction. Leuk. and Lymph. 17, Suppl. (1991), 161–173.

Ezdinli, E. Z., L. Stutzman, C. W. Aungst, D. Firat: Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer (Philad.) 23 (1969), 900–909.

Faguet, G. B.: Chronic lymphocytic leukemia: An updated review. J. clin. Oncol. 12 (1994), 1974–1990.

French Cooperative Group on chronic lymphocytic leukemia. Effectiveness of „CHOP” regimen in advanced untreated chronic lymphocytic leukemia: Results from a randomized clinical trial. Lancet I (1986), 1346–1349.

French Cooperative Group on CLL, S. Johnson, A. G. Smith, H. Löffler, E. Ösby, G. Juliusson, B. Emmerich, P. J. Wyld, W. Hiddemann: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347 (1996) 1432–1438.

Hallek, M., L. Wanders, M. Ostwald, R. Busch, R. Senekowitsch, S. Stern, H. D. Schick, I. Kuhn-Hallek, B. Emmerich: Serum β2-microglobulin and serum thymidine 0 kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk. and Lymph. 22 (1996), 439–447.

Han, T., E. Z. Ezdinli, K. Shimaoka, D. V. Desai: Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer (Philad.) 31 (1973), 502–508.

Harris, N. L., E. S. Jaffe, H. Stein, P. M. Banks, J. K. C. Chan, M. L. Cleary, G. Delsol, C. De Wolf-Peeters, B. Falini, K. C. Gatter, T. M. Grogan, P. G. Isaacson, D. M. Knowles, D. Y. Mason, H. K. Müller-Hermelink, S. A. Pileri, M. A. Piris, E. Ralfkiaer, R. A. Warnke: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361–1392.

International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann. intern. Med. 110 (1989), 236–238.

Jaksic, B., M. Brugiatelli, I. Krc, H. Losonczi, J. Holowiecki, B. Labar, V. Jacopino, D. Lutz: Comparison of high-dose chlorambucil versus Binet’s modified CHOP regimen in B-cell chronic lymphocytic leukemia in advanced phase: Results of an international multicentric randomized trial. Blood 86 Suppl. 1 (1995, 607a.

Keating, M. J., H. Kantarjian, M. Talpaz, J. Redman, C. Koller, B. Barlogie, W. Velasquez, W. Plunkett, E. J. Freireich, K. B. McCredie: Fludarabine — a new agent with major activity against chronic lymphocytic leukemia. Blood 74 (1989), 19–25.

Knospe, W. H., V. Loeb jr., C. M. Huguley jr.: Biweekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer (Philad.) 33 (1974), 555–562.

Michallet, M., E. Archimbaud, G. Bandini, P. A. Rowlings, H. J. Deeg, G. Gahrton, E. Monteerrat, C. Rozman, A. Gratwohl, P. Gale: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann. intern. Med. 124 (1996), 311–315.

Montserrat, E., A. Alcalá, C. Alonso, J. Besalduch, J. M. Moraleda, J. García-Conde, M. Gutierrez, F. Gomis, J. Garijo, M. C. Guzmán, J. Estapé, C. Rozman and participating members of Pethema, Spanish Society of Hematology: A randomized trial comparing chlorambucil plus prednisone vs. cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv. Rev. franç. Hémat. 30 (1988), 429–432.

Montserrat, E., A. Alcalá, R. Parody, A. Domingo, J. García-Conde, J. Bueno, C. Ferrán, M. A. Sanz, M. Giralt, D. Rubio, I. Antón, J. Estapé, C. Rozman and participating members of Pethema; Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology: Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer (Philad.) 56 (1985), 2369–2375.

Montserrat, E., C. Rozman: Chronic lymphocytic leukemia: Present status. Ann. Oncol. 6 (1995) 219–235.

O’Brien, S., A. del Giglio, M. Keating: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85 (1995), 307–318.

Provan, D., L. Bartlett-Pandite, C. Zwicky, D. Neuberg, A. Maddocks, P. Corradini, R. Soiffer, J. Ritz, L. M. Nadler, J. G. Gribben: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88 (1996), 2228–2235.

Rai, K. R., A. Sawitsky, E. P. Cronkite, A. D. Chanana, R. N. Levy, B. S. Pasternack: Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975), 219–234.

Raphael, B., J. W. Anderson, R. Silber, M. Oken, D. Moore, J. Bennett, H. Bonner, R. Hahn, W. H. Knospe, J. Mazza, J. Glick: Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical. J. clin. Oncol. 9 (1991), 770–776.

Rozman, C., E. Montserrat: Chronic lymphocytic leukemia. New Engl. J. Med. 333 (1995), 1052–1057.

Sawitsky, A., K. R. Rai, O. Glidewell, R. T. Silver and participating members of CALGB (Cancer and Leukemia Group B): Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50 (1977), 1049–1059.

Tallman, M. S., D. Hakimian: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 86 (1995), 2463–2474.